Jane Street’s Axsome Therapeutics AXSM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $98.9M | Buy |
403,995
+399,917
| +9,807% | +$86.7M | 0.01% | 944 |
|
|
2026
Q1 | $689K | Sell |
4,078
-133,205
| -97% | -$23M | ﹤0.01% | 7302 |
|
|
2025
Q4 | $25.1M | Buy |
137,283
+6,438
| +5% | +$899K | ﹤0.01% | 1424 |
|
|
2025
Q3 | $15.9M | Buy |
+130,845
| New | +$14.7M | ﹤0.01% | 1877 |
|
|
2025
Q2 | – | Sell |
-90,141
| Closed | -$9.54M | – | 9596 |
|
|
2025
Q1 | $10.5M | Buy |
90,141
+11,692
| +15% | +$1.33M | ﹤0.01% | 1930 |
|
|
2024
Q4 | $6.64M | Sell |
78,449
-51,648
| -40% | -$4.75M | ﹤0.01% | 2318 |
|
|
2024
Q3 | $11.7M | Sell |
130,097
-38,337
| -23% | -$3.35M | ﹤0.01% | 1756 |
|
|
2024
Q2 | $13.6M | Sell |
168,434
-30,645
| -15% | -$2.27M | ﹤0.01% | 1684 |
|
|
2024
Q1 | $15.9M | Buy |
199,079
+106,248
| +114% | +$8.92M | ﹤0.01% | 1379 |
|
|
2023
Q4 | $7.39M | Sell |
92,831
-32,750
| -26% | -$2.19M | ﹤0.01% | 2336 |
|
|
2023
Q3 | $8.78M | Sell |
125,581
-150,321
| -54% | -$11.2M | ﹤0.01% | 1924 |
|
|
2023
Q2 | $19.8M | Buy |
275,902
+254,158
| +1,169% | +$18.7M | 0.01% | 1215 |
|
|
2023
Q1 | $1.34M | Sell |
21,744
-154,155
| -88% | -$10.1M | ﹤0.01% | 4480 |
|
|
2022
Q4 | $13.6M | Sell |
175,899
-6,971
| -4% | -$417K | 0.01% | 1320 |
|
|
2022
Q3 | $8.16M | Buy |
182,870
+140,975
| +336% | +$7.04M | ﹤0.01% | 1927 |
|
|
2022
Q2 | $1.6M | Buy |
41,895
+1,336
| +3% | +$42.3K | ﹤0.01% | 4573 |
|
|
2022
Q1 | $1.68M | Sell |
40,559
-358,235
| -90% | -$11.1M | ﹤0.01% | 5081 |
|
|
2021
Q4 | $15.1M | Buy |
398,794
+105,462
| +36% | +$3.88M | 0.01% | 1437 |
|
|
2021
Q3 | $9.67M | Buy |
293,332
+190,621
| +186% | +$7.43M | ﹤0.01% | 1844 |
|
|
2021
Q2 | $6.93M | Buy |
102,711
+10,539
| +11% | +$632K | ﹤0.01% | 2181 |
|
|
2021
Q1 | $5.22M | Buy |
92,172
+19,918
| +28% | +$1.4M | ﹤0.01% | 2358 |
|
|
2020
Q4 | $5.89M | Sell |
72,254
-107,001
| -60% | -$8M | ﹤0.01% | 1936 |
|
|
2020
Q3 | $12.8M | Buy |
179,255
+119,216
| +199% | +$9.29M | 0.01% | 1045 |
|
|
2020
Q2 | $4.94M | Sell |
60,039
-50,121
| -45% | -$3.86M | ﹤0.01% | 1864 |
|
|
2020
Q1 | $6.48M | Sell |
110,160
-57,496
| -34% | -$4.68M | 0.01% | 1015 |
|
|
2019
Q4 | $17.3M | Buy |
167,656
+155,206
| +1,247% | +$6.27M | 0.02% | 430 |
|
|
2019
Q3 | $252K | Buy |
12,450
+392
| +3% | +$10.1K | ﹤0.01% | 4361 |
|
|
2019
Q2 | $310K | Sell |
12,058
-7,092
| -37% | -$142K | ﹤0.01% | 4153 |
|
|
2019
Q1 | $273K | Buy |
+19,150
| New | +$178K | ﹤0.01% | 4356 |
|
Other funds holding AXSM
DTC
Jane Street's AXSM Position: Q2 2026 in Review
Jane Street increased its Axsome Therapeutics (AXSM) stake by 9,807% in Q2 2026, buying an estimated $86.7M and bringing the position to 403,995 shares worth $98.9M. The position accounts for 0.01% of the portfolio, ranked #944.
Jane Street first reported a position in AXSM in Q1 2019 and has held it in 29 quarters since. 461 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.
- Jane Street held 403,995 shares of Axsome Therapeutics worth $98.9M as of Q2 2026.
- Jane Street bought 399,917 Axsome Therapeutics shares in Q2 2026, an estimated $86.7M.
- Axsome Therapeutics made up 0.01% of Jane Street's portfolio in Q2 2026, its #944 holding.
- Jane Street first reported a position in Axsome Therapeutics in Q1 2019 and has held it in 29 quarters since.
- 461 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.
Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.